Aberdeen Group plc Trims Stake in Biogen Inc. $BIIB

Aberdeen Group plc reduced its stake in Biogen Inc. (NASDAQ:BIIB) by 11.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 138,865 shares of the biotechnology company’s stock after selling 17,890 shares during the period. Aberdeen Group plc’s holdings in Biogen were worth $19,452,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of BIIB. Elevation Point Wealth Partners LLC purchased a new position in shares of Biogen during the 2nd quarter worth approximately $25,000. Rothschild Investment LLC grew its stake in Biogen by 64.7% in the second quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 88 shares during the period. NewSquare Capital LLC grew its stake in Biogen by 134.6% in the second quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 140 shares during the period. WFA of San Diego LLC bought a new position in Biogen in the second quarter worth $32,000. Finally, True Wealth Design LLC lifted its position in Biogen by 62.9% during the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 90 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BIIB. Wall Street Zen downgraded shares of Biogen from a “buy” rating to a “hold” rating in a research report on Sunday, November 9th. Tudor Pickering set a $201.00 price objective on shares of Biogen in a report on Monday, February 9th. Royal Bank Of Canada lifted their target price on shares of Biogen from $217.00 to $233.00 and gave the company an “outperform” rating in a report on Monday, February 9th. HSBC reissued a “reduce” rating and issued a $143.00 price target (down from $144.00) on shares of Biogen in a research report on Wednesday, December 10th. Finally, Piper Sandler raised their price objective on Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a research report on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $205.84.

Insider Buying and Selling

In other Biogen news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider owned 8,043 shares in the company, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.18% of the company’s stock.

Biogen Price Performance

Shares of BIIB opened at $194.13 on Thursday. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41. The company has a market capitalization of $28.49 billion, a P/E ratio of 22.04, a price-to-earnings-growth ratio of 1.55 and a beta of 0.16. The firm has a 50 day moving average of $179.27 and a 200 day moving average of $160.46. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same period last year, the business posted $3.44 EPS. The company’s revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities research analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.